Evidence map›Paper›PMID 33642133›Full record

ArticleRevista espanola de geriatria y gerontologia

VitaminD supplementation for the prevention and treatment of COVID-19: a position statement from the Spanish Society of Geriatrics and Gerontology.

Francisco J Tarazona-Santabalbina, Leonor Cuadra, José Manuel Cancio, Ferran Roca Carbonell, Juan Manuel Pérez-Castejón Garrote, Álvaro Casas-Herrero, Nicolás Martínez-Velilla, José Antonio Serra-Rexach, Francesc Formiga

Open access · greenAbstract readConsensus Statement
In one paragraph

Article in Revista espanola de geriatria y gerontologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Francisco J Tarazona-SantabalbinaGeriatric Service, Hospital Universitario de la Ribera, Alzira, Valencia, Spain. CIBERFES, Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable, Madrid, Spain. Electronic address: fjtarazonas@gmail.com.
Leonor CuadraDepartament of Geriatric Medicine and Palliative Care, Badalona Serveis Assistencials, Barcelona, Spain. Catalonia Geriatrics and Gerontology Society, Barcelona, Spain.
José Manuel CancioCentro Sociosanitario El Carme, Servicio de Geriatría y Cuidados Paliativos de BSA (Badalona Servicios Asistenciales), Badalona, Spain; Badalona Welfare Services: Badalona Serveis Assistencials SA, Badalona, Spain.
Ferran Roca CarbonellServicio de Geriatría Hospital Universitari de la Santa Creu, Vic, Spain; Hospital Universitari de Vic: Hospital General de Vic, Spain.
Juan Manuel Pérez-Castejón GarroteDoctor en Medicina por la UB Especialista en Geriatria, Jefe del Servicio de Geriatria y Cuidados Paliativos de Badalona Serveis Assistencials BSA, CSS El Carme Badalona, Spain; Badalona Welfare Services: Badalona Serveis Assistencials SA, Badalona, Spain.
Álvaro Casas-HerreroNavarrabiomed, Complejo Hospitalario de Navarra (CHN), (UPNA), IdiSNA, Pamplona, Spain; CIBER of Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain; Hospital de Navarra: Complejo Hospitalario de Navarra, Spain.
Nicolás Martínez-VelillaNavarrabiomed, Complejo Hospitalario de Navarra (CHN), (UPNA), IdiSNA, Pamplona, Spain; CIBER of Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain; Hospital de Navarra: Complejo Hospitalario de Navarra, Spain.
José Antonio Serra-RexachJefe del Servicio de Geriatría Hospital General Universitario Gregorio Marañón Profesor Titular de Medicina, Departarmento de Medicina, Facultad de Medicina Universidad Complutense CIBER-Fragilidad y Envejecimiento Saludable Madrid, Spain; Hospital General Universitario Gregorio Marañón: Hospital General Universitario Gregorio Maranon, Spain.
Francesc FormigaPrograma de Geriatría, Servicio medicina Interna, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Systemic Diseases and Ageing Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Ageing Program, Translational Medicine Area, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
Badalona Serveis Assistencials · ESCentro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable · ESHospital Universitari de Vic · ESInstitut d'Investigació Biomédica de Bellvitge · ESNavarrabiomed · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) produces severe respiratory symptoms such as bilateral pneumonia associated to a high morbidity and mortality, especially in patients of advanced age. Vitamin D deficiency has been reported in several chronic conditions associated with increased inflammation and dysregulation of the immune system. Vitamin D in modulates immune function too. Vitamin D receptor (VDR) is expressed by most immune cells, including B and T lymphocytes, monocytes, macrophages, and dendritic cells and the signalling of vitamin D and VDR together has an anti-inflammatory effect. Some studies have reported that vitamin D treatment could be useful for the prevention and treatment of COVID-19 because vitamin D plays an important role as a modulator of immunocompetence. Over the last few months, some studies have hypothesized the possible beneficial effect of vitamin D supplementation in patients with COVID-19 in order to improve the immune balance and prevent the hyperinflammatory cytokine storm. Some preliminary studies have already shown promising results with vitamin D supplementation in hospitalized COVID-19 patients. Vitamin D should be administered daily until adequate levels are achieved due to vitamin D behaves as a negative acute phase reactant (APR). Despite the lack of evidence on specific doses of vitamin D to treat COVID-19 in older adults, authors consider it is necessary to standardize the use in clinical practice. These recommendations advice supplement vitamin D in a protocoled fashion based on expert opinions, level of evidence 5.

Indexed as

Cytokine Release SyndromeDietary SupplementsGeriatricsAgedCOVID-19HumansReceptors, CalcitriolSocieties, MedicalSpainVitamin DVitamin D DeficiencyVitaminsReceptors, CalcitriolVitamin DVitaminsAdultos mayoresCOVID-19FragilidadFrailtyOlder adultsSARS-CoV-2Vitamina DVitamin D

Identifiers

PMID33642133
PMCPMC8055189
OpenAlexW3133269082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.